Full-year results reflected the £5m milestone payment from Pharmaxis in late 2017, with adjusted pre-tax profits of £1.7m, which compared with a loss of £3.25m in FY 2016. Year-end cash was c.£0.3m better than forecast at £6.8m, providing the company with a cash runway well into 2019, which should cover the H1 2019 readout of its Phase IIa trial for SNG001 in COPD and a possible milestone payment in 2018 from Pharmaxis, relating to the 17% retained interest in th
15 Mar 2018
Year-end cash ample to complete Phase IIa
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Year-end cash ample to complete Phase IIa
Synairgen plc (SNG:LON) | 6.7 0 0.0% | Mkt Cap: 13.6m
- Published:
15 Mar 2018 -
Author:
Cavendish Research -
Pages:
10
Full-year results reflected the £5m milestone payment from Pharmaxis in late 2017, with adjusted pre-tax profits of £1.7m, which compared with a loss of £3.25m in FY 2016. Year-end cash was c.£0.3m better than forecast at £6.8m, providing the company with a cash runway well into 2019, which should cover the H1 2019 readout of its Phase IIa trial for SNG001 in COPD and a possible milestone payment in 2018 from Pharmaxis, relating to the 17% retained interest in th